GRI Bio (NASDAQ: GRIM) Advances UAE Patent for Innovative NKT Cell Agonists
Key Developments GRI Bio (NASDAQ: GRIM) announced it has received a notice of allowance for its patent application in the United Arab Emirates. The patent covers novel type 2 diverse natural killer T (NKT) cell agonists designed for treating inflammatory diseases. This approval strengthens GRI Bio’s intellectual property rights regarding its immune cell modulation platform. The granted claims enhance GRI Bio’s presence in a rapidly expanding international market. This strategic…
